CN106360732A - Linoleic and linolenic acid, preparation method thereof and linoleic and linolenic acid preparation - Google Patents
Linoleic and linolenic acid, preparation method thereof and linoleic and linolenic acid preparation Download PDFInfo
- Publication number
- CN106360732A CN106360732A CN201610794308.7A CN201610794308A CN106360732A CN 106360732 A CN106360732 A CN 106360732A CN 201610794308 A CN201610794308 A CN 201610794308A CN 106360732 A CN106360732 A CN 106360732A
- Authority
- CN
- China
- Prior art keywords
- acid
- double
- asias
- supplement
- linoleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 title claims abstract description 75
- 235000020661 alpha-linolenic acid Nutrition 0.000 title claims abstract description 44
- 229960004488 linolenic acid Drugs 0.000 title claims abstract description 44
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 title claims abstract description 32
- 235000020778 linoleic acid Nutrition 0.000 title claims abstract description 32
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 title abstract description 13
- 239000008157 edible vegetable oil Substances 0.000 claims abstract description 51
- 238000007127 saponification reaction Methods 0.000 claims abstract description 26
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 238000000746 purification Methods 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims description 182
- 239000013589 supplement Substances 0.000 claims description 107
- 241001614291 Anoplistes Species 0.000 claims description 90
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 37
- 229930195729 fatty acid Natural products 0.000 claims description 37
- 239000000194 fatty acid Substances 0.000 claims description 37
- -1 fatty alcohol citrate Chemical class 0.000 claims description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 230000007062 hydrolysis Effects 0.000 claims description 16
- 238000006460 hydrolysis reaction Methods 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 11
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical group OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 8
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 125000005456 glyceride group Chemical group 0.000 claims description 7
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 6
- 235000004443 Ricinus communis Nutrition 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 238000006386 neutralization reaction Methods 0.000 claims description 6
- 229920000223 polyglycerol Polymers 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 6
- 241000628997 Flos Species 0.000 claims description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 4
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 4
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 229960004999 lycopene Drugs 0.000 claims description 4
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 4
- 235000012661 lycopene Nutrition 0.000 claims description 4
- 239000001751 lycopene Substances 0.000 claims description 4
- 239000008347 soybean phospholipid Substances 0.000 claims description 4
- 239000011573 trace mineral Substances 0.000 claims description 4
- 235000013619 trace mineral Nutrition 0.000 claims description 4
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 4
- 241000965254 Apostichopus japonicus Species 0.000 claims description 3
- 244000221226 Armillaria mellea Species 0.000 claims description 3
- 235000011569 Armillaria mellea Nutrition 0.000 claims description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 3
- 241000756943 Codonopsis Species 0.000 claims description 3
- 244000131316 Panax pseudoginseng Species 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 3
- 241000241413 Propolis Species 0.000 claims description 3
- 229930014669 anthocyanidin Natural products 0.000 claims description 3
- 150000001452 anthocyanidin derivatives Chemical class 0.000 claims description 3
- 235000008758 anthocyanidins Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 229940069949 propolis Drugs 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- 244000089742 Citrus aurantifolia Species 0.000 claims 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 22
- 201000010099 disease Diseases 0.000 abstract description 19
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 11
- 241001465754 Metazoa Species 0.000 abstract description 10
- 238000013459 approach Methods 0.000 abstract description 7
- 210000004204 blood vessel Anatomy 0.000 abstract description 7
- 230000003449 preventive effect Effects 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 238000007710 freezing Methods 0.000 abstract description 3
- 230000008014 freezing Effects 0.000 abstract description 3
- 230000037356 lipid metabolism Effects 0.000 abstract description 3
- 230000003301 hydrolyzing effect Effects 0.000 abstract 3
- 230000032683 aging Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 26
- 235000019198 oils Nutrition 0.000 description 26
- 239000003925 fat Substances 0.000 description 24
- 235000019197 fats Nutrition 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 235000013305 food Nutrition 0.000 description 20
- 239000003814 drug Substances 0.000 description 18
- 230000036541 health Effects 0.000 description 18
- 150000004665 fatty acids Chemical class 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000002526 effect on cardiovascular system Effects 0.000 description 12
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 11
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 11
- 235000012054 meals Nutrition 0.000 description 11
- 208000024172 Cardiovascular disease Diseases 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 150000002632 lipids Chemical group 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- 208000026106 cerebrovascular disease Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 235000015112 vegetable and seed oil Nutrition 0.000 description 9
- 239000008158 vegetable oil Substances 0.000 description 9
- 235000004626 essential fatty acids Nutrition 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 238000005457 optimization Methods 0.000 description 8
- 208000016097 disease of metabolism Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 201000005577 familial hyperlipidemia Diseases 0.000 description 7
- 208000030159 metabolic disease Diseases 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 230000035764 nutrition Effects 0.000 description 7
- 210000000582 semen Anatomy 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102100027378 Prothrombin Human genes 0.000 description 5
- 108010094028 Prothrombin Proteins 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229940039716 prothrombin Drugs 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000019802 Sexually transmitted disease Diseases 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000014593 oils and fats Nutrition 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000009693 chronic damage Effects 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013486 Distractibility Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 240000007930 Oxalis acetosella Species 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- KEVIIPRPZFKDMS-UHFFFAOYSA-N carbonic acid;octadecanoic acid Chemical compound OC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O KEVIIPRPZFKDMS-UHFFFAOYSA-N 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- TVQGDYNRXLTQAP-UHFFFAOYSA-N ethyl heptanoate Chemical compound CCCCCCC(=O)OCC TVQGDYNRXLTQAP-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008041 oiling agent Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ZYFGTJPGLOESBV-UHFFFAOYSA-N propanedioic acid;sodium Chemical compound [Na].OC(=O)CC(O)=O ZYFGTJPGLOESBV-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008802 xuezhikang Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the technical field of linoleic and linolenic acid, in particular to linoleic and linolenic acid, a preparation method thereof and a linoleic and linolenic acid preparation. The linoleic and linolenic acid is prepared by the method including the steps: sequentially performing hydrolytic saponification, neutralizing purification and freezing separation for edible vegetable oil under existing conventional technical conditions; finally preparing pure linoleic acid and alpha-linolenic acid, namely, preparing pure linoleic and linolenic acid. The linoleic and linolenic acid is characterized in that emulsifiers accounting for 0.5%-1% of the edible vegetable oil are firstly added into the edible vegetable oil in hydrolytic saponification, and then conventional hydrolytic saponification is performed. The method for producing the linoleic and linolenic acid is rapid, production time is effectively shortened, and production efficiency is improved. The linoleic and linolenic acid preparation can serve as a correcting agent and a supplementing agent for the linoleic and linolenic acid and can function in improving lipid metabolism, maintaining blood vessel elasticity, resisting aging, preventing diseases and performing preventive treatment of the diseases, edible animal and plant components beneficial to bodies are added, and a novel approach is provided for accepting and taking special nutrient or treatment components by human bodies.
Description
Technical field
The present invention relates to double Asia technic acid field, it is a kind of double Asia acid and preparation method thereof and double Asias acid supplement.
Background technology
Double Asia acid are linoleic acid and alpha linolenic acid, and people are easy to associate dining table edible oil, and really, the two is in vegetable oil
In account for certain proportion.For the fatty acid in edible oil, medical science, threpsology, clinical nutriology, epidemiology are finalized, right
In health, fatty acid is a double-edged sword: improper body can be caused with chronic injury, Chinese residents ordinary meal when edible
Incorrect crowd is up to several hundred million for lipid structure, and subject matter is that linoleic acid is excessive, alpha linolenic acid is not enough, and this is to cause state's human blood
One of fat exception crowd's quantity remains high, and the major reason to rejuvenation fast development.If edible reasonable, balance is taken the photograph
Take fatty acid especially to balance the double sub- acid of picked-up, body is had various health-care, wherein attention rate and degree of recognition highest are pre-
Prevent and improve " three high ", especially improve dyslipidemia.Scientific definition by fatty acid to health be a double-edged sword be to have
According to, rationally picked-up is health product；Incorrect eating may result in chronic disease.So-called incorrect eating mainly has two sides
Face: one is excessive, two is that double Asias acid ratio example is unreasonable.Fat, protein, carbohydrate are referred to as three big energy battalion of human body
Support element, be the basis of the big metabolism of liver three, especially fatty acid (edible oil) play during human physiological metabolism extremely heavy
The effect wanted.
Correct picked-up double Asias acid, except playing an important role in terms of prevention and treatment cardiovascular and cerebrovascular disease, also has it
The function of its aspect, such as enhance immunity, controlling gene expression, the coordination physiological interaction of iuntercellular, maintenance rhodopsin
Normal function, synthesising prostate, improve carbohydrate metabolism and insulin sensitivity and avoid lack essential fatty acid caused by many
Plant disease etc..With scientific and technical continuous development, also constantly it is being found and is confirming with regard to the new function of essential fatty acid；
The double sub- acid of incorrect picked-up can cause chronic injury to human body, except people it is well recognized that total to fat
Amount and satisfied fatty acid will control outside picked-up quantity, and double Asia acid belong to polyunsaturated fatty acid, there is also and are also easy to produce lipid mistake
Problem of oxidation.Improve lipid aspects in attention rate highest, excessive linoleic acid is reducing harmful low-density lipoprotein
While white, favourable to human body high density lipoprotein also decreases, induction inflammation, immunosuppressant simultaneously；Excessive α
Linolenic acid has the negative interaction of higher suppression cellular immunity.Just because of this, the ratio of omega 3 and omega 6 is to closing weight
Will be it is necessary to overcome the puzzlement that the two brings to body when individually eating.While double sub- acid New function are constantly found, should
This notices that double Asia acid are antioxidant in itself, excessive prooxidant will be become by antioxidation, human body itself is resisted
Oxidation system can produce certain suppression and interference, quantitative edible critically important.
The double sub- acid that there are about half in the meals of Chinese Urban Residents derives from edible oil, and half in addition derives from other
Food.In addition to the only a few food such as water, ethanol, sugar, including water fruits and vegetables, grain, almost all of food all contains
A number of fat includes Animal fat, and it is extremely wide that food fat includes double sub- acid distribution faces, pulls one hair and move the whole body it is impossible to carve
Meaning selects, and otherwise can produce significant impact to " quality of life " or even " Happiness Index ", belong to uncontrollable and have non-adjustable
Section property.But the absorption of edible oil is can to project and ask with manual control it is important to the fatty acid structure of edible oil is especially unreasonable
Topic is that the ratio of double sub- acid ω 6 and ω 3 is excessive, and linoleic acid is excessive, alpha linolenic acid famine, and this dietary fat structure is deepened
The fat intake total amount exceeded order of severity that human body is worked the mischief.
At present in the vegetable oil of single variety, double Asias acid ratio example is extremely unreasonable, including transformed variety, does not have a kind of fat
Fat acid composition complies fully with the standard of nutritionist: expensive olive oil, Oleum Camelliae double Asia acid very low, especially lack ω 3
The alpha linolenic acid of series, main component is that human body being capable of itself synthesis Oleic acid；Oleum Arachidis hypogaeae semen is favored by China resident very much, but still
There are two problems, one is that alpha linolenic acid content is extremely low, less than 1%, need well below human body, satisfied fatty acid is close
20%, it is two times about of general edible oil kind, close to three times of Oleum Brassicae campestriss, the satisfied fatty acid phase that 3 jin of Oleum Arachidis hypogaeae semen contains
When in 1 jin of Adeps Sus domestica, Oleum Arachidis hypogaeae semen is overeated to be equal to and eaten animal oil；The satisfied fatty acid ratio of Testa oryzae oil (Rice oil) is also slightly above
Oleum Arachidis hypogaeae semen；Other daily consumption frequencies higher vegetable oil such as Semen Maydis oil, Oleum Helianthi and the Oleum sesami seldom eating, Flos Carthami
In addition to alpha linolenic acid composition is relatively low, its linoleic absolute ratio equally substantially exceeds China residence to the kinds such as oil, Oleum Vitis viniferae
The physiological need of the people: Semen Lini oil, perilla oil be another extreme although general lack of α in Chinese residents ordinary meal structure
Linolenic acid, but in edible oil, more than 50% alpha linolenic acid content can make the ratio of whole meals ω 6 and ω 3 in most cases
The lower limit that value requires less than threpsology, has the lipid peroxidation risk bigger than excessive linoleic acid；The linoleic acid of soybean oil
It is better than general kind with alpha linolenic acid ratio, but still has a certain distance with desired proportions, subject matter is double sub- acid total amount mistake
Greatly, close to 60%, the daily intake per capita according to healthy guide specification controls in 30 grams/day total content, and double Asia acid can be taken in
8%.In addition to vegetarian, internal lipid peroxidation is nearly unavoidable.It is many that Chinese residents have all understood that oil is eaten now
Bad, but the amount of eating is still larger, double sub- acid absorption ratios are incorrect or linolenic acid is taken in excessive, are all cardiovascular and cerebrovascular diseases
Old and feeble major reason, is the major reason of multiple chronic diseases with human body cell；Petiolus Trachycarpi oil is that a price is relatively low, many meal
The oil product that shop and food processing are commonly used, is to adulterate the important source material of mixed oil, Petiolus Trachycarpi oil except be practically free of alpha linolenic acid it
Outward, satisfied fatty acid ratio is close with animality edible oil.In single plant oil double Asia acid be not be exactly less or ratio not
Properly, for solve problem, there is a kind of mixed oil in country, many Oils and fats enterprises short-sighted, go after profit or gain in addition no good behavior with
And many profound complicated factors such as the disappearance of public welfare edible oil work of popular science, this is health originally to cause " mixed oil "
The feature kind of concept deviate from and is correctly oriented and extensively misread by consumer.
The edible oil problem of China is quite serious, has become as in food service industry and misleads the most serious, consumer perceptions' mistake
Area is most, coverage is maximum, the time is the longest, and so far still in lasting " severely afflicated area ".The numerous common people to this trouble waters
Though there being puzzlement, but have no way out.Purifying edible oil market environment by the supply agent of edible oil or edible oil is an accepting a heavy burden
Road is remote, but the great achievement of work is in the contemporary generation, profit is in the future thousands of years.Eat oil no minor matter, that edible oil Resolving probiems are not good, our health is just not
May not stay sorry.
Certainly, provide the form that double Asia acid can be vegetable oil, but to prepare as mixed oil and to meet proportion requirement
Double sub- acid vegetable oil are it is difficult to popularize.The ratio of omega 3: omega 6=1:4 to 6 is just proposed by the UN-World Health Organisation
Example requires, and except indivedual oil products, majority does not reach requirement, can not meet the market demand.Nearly all contain in a lot of vegetable oil at present
Linoleic acid, alpha-linolenic acid seldom or does not have, and only Semen Lini oil (flax oil) is many containing alpha-linolenic acid, but linoleic acid is very little.
People are eaten for a long time the single edible oil of essential fatty acid, and deeply hurt is exactly cardiovascular and cerebrovascular vessel, carrying so that with living standard
Height, cardiovascular and cerebrovascular vessel sickness rate more and more higher is corollary.
According to the present situation of our state food processing industries, a large amount of food produced all lack double sub- acid very much.Originally put
Foster domestic animal, under the stable breeding of man-made feeds, almost searches for food less than the food rich in Ou Mijia -3.Such food chain interruption,
Lead to the ratio of the essential fatty acid in our meals (human body itself can not generate, and food can only be relied on to obtain) ω -3 and ω -6
Serious unbalance, is up to 1:30, even 1:50 unexpectedly in the ratio of China.The safflower oil ω -3 being advocated by people and the ratio of ω -6
Even as high as more than 1:200, eats more more unfavorable to body, whole people's Ou Mijia -6 fatty acid intake is exceeded, has a strong impact on
The health.
Our compatriots wallow among motherland's cooking culture of extensive knowledge and profound scholarship always, " can eat is good fortune, the how not bad dish of oil "
Meals in, formed many incorrect dietaries, made the sickness rate such as cardiovascular and cerebrovascular disease, senile dementia, cancer continuous
Rise, become the first in the world.In addition to various pollutions, double Asias acid ratio example is unreasonable to be one of the reason cause this result.
Double Asia acid are not medicines, are not additives, are the important component in andvegetable fats, it is unusual to play in health
Role, from cradle to grave always along with we and affect us, darkling protect our health.Although simply impact human body
One of many factors of health, but dispensable material by no means.Supplement double Asia acid and be allowed to essential fatty acid holding in vivo
Balance, is to reduce disease, the important means kept fit.
Content of the invention
The invention provides a kind of double Asia acid and preparation method thereof and double Asias acid supplements, overcome above-mentioned prior art no
Foot, it current resident of effectively solving can absorb pair ratio seriously inharmonic problem of sub- acid from meals and edible oil, there is provided
A kind of method producing double sub- acid efficiency highs and the double Asia acid of effectively supplementary needed by human body make the double Asia acid of human intake reasonably double
Sub- acid supplement.
One of technical scheme is realized by following measures: a kind of double sub- acid, obtains as follows:
Edible vegetable oil is hydrolyzed saponification, neutralization purification, freeze and separate successively by existing routine techniquess condition, finally
To linoleic acid and the alpha-linolenic acid of sterling, that is, obtain the double sub- acid of sterling, theing improvement is that of the present invention is anti-in hydrolysis saponification
Ying Zhong, first adds the emulsifying agent of edible vegetable oil 0.5% to 1% in edible vegetable oil, then carries out the hydrolysis saponification of routine
Reaction.
Further optimization and/or improvements to foregoing invention technical scheme one of are presented herein below:
Mentioned emulsifier is monoglyceride, sodium stearate, Palmic acid citrate, sucrose palmitate, fatty alcohol citric acid
Ester, fatty glyceride, glycerol monolaurate, polyglycereol castor fatty acid ester, polyglycerol cetylate, high-purity powder Semen sojae atricolor
Phospholipid, dextrin, span Tweenses, sucrose polyfatty acid esterses, glycerol fatty acid ester, polyglyceryl fatty acid ester, sorbitan fatty acid
Ester or citrate.
The two of technical scheme are realized by following measures: a kind of preparation method of double sub- acid, press
The method of stating is carried out: by edible vegetable oil by existing routine techniquess condition be hydrolyzed successively saponification, neutralization purification, freezing
Separate, finally obtain linoleic acid and the alpha-linolenic acid of sterling, that is, obtain the double sub- acid of sterling, the present invention thes improvement is that
In hydrolysis saponification, in edible vegetable oil, first add the emulsifying agent of edible vegetable oil 0.5% to 1%, then carry out routine
Hydrolysis saponification.
To foregoing invention technical scheme two further optimization and/or improvements are presented herein below:
Mentioned emulsifier is monoglyceride, sodium stearate, Palmic acid citrate, sucrose palmitate, fatty alcohol citric acid
Ester, fatty glyceride, glycerol monolaurate, polyglycereol castor fatty acid ester, polyglycerol cetylate, high-purity powder Semen sojae atricolor
Phospholipid, dextrin, span Tweenses, sucrose polyfatty acid esterses, glycerol fatty acid ester, polyglyceryl fatty acid ester, sorbitan fatty acid
Ester or citrate.
The three of technical scheme are realized by following measures: a kind of double Asias of one of use technical scheme
Pair Asia acid supplement that acid obtains, obtains as follows: the linoleic acid of addition sterling or alpha-linolenic acid in double sub- acid, and regulation α-
Linolenic acid is 1:0.5 to 3 with linoleic mass ratio, obtains double Asias acid supplement.
To foregoing invention technical scheme three further optimization and/or improvements are presented herein below:
Above-mentioned double Asias acid supplement exists in oily form.
1% to 10% Flos Carthami extract is added in the above-mentioned acid supplement to double Asias；Or/and, add in the acid supplement of double Asias
1% to 10% lycopene；Or/and, add 1% to 30% phylloxanthin in the acid supplement of double Asias；Or/and, to double sub- acid
1% to 40% anthocyanidin is added in preparation；Or/and, add 1% to 20% Radix Ginseng powder in the acid supplement of double Asias；Or/and,
1% to 20% Stichopus japonicus powder is added in the acid supplement of double Asias；Or/and, add 1% to 20% Radix Codonopsis in the acid supplement of double Asias
Powder；Or/and, add 1% to 20% Armillaria mellea in the acid supplement of double Asias；Or/and, to double Asia acid supplements in add 1% to
40% lecithin；Or/and, add 1% to 20% propolis in the acid supplement of double Asias.
1% to 5% protein is added in the above-mentioned acid supplement to double Asias；Or/and, add 0.1% in the acid supplement of double Asias
To 10% vitamin b；Or/and, add 1% to 10% vitamin c in the acid supplement of double Asias；Or/and, to double Asias acid supplement
The vitamin a of middle addition 0.1% to 5%；Or/and, add 0.1% to 5% vitamin d in the acid supplement of double Asias；Or/and,
Add trace element in the acid supplement of double Asias.
The method that the present invention produces double sub- acid is quick, effectively shortens production time, improve production efficiency, and the present invention's is double sub-
Acid supplement can effectively solve the problem that double sub- acid inharmonic problems of picked-up ratio in resident's ordinary meal edible oil, can be used as edible
The a kind of of oil corrects agent and supplement, directly can also provide prevention and treatment for metabolic disease, can play and improve lipid generation
Thank, safeguard blood vessel elasticity, defying age and disease preventing and treating and the effect of preventive treatment of disease, the purpose preventing and treating hyperlipemia can be reached,
Safety is good, has broad application prospects, and belongs to natural " green " composition, is simultaneously introduced the edible animals and plants that body is beneficial to
Composition, two life nucleic can be played on the basis of maintaining self-acting to the new synergism adding composition, strengthening
The physiological function of these edible animals and plants compositions, accepts and takes in special dietary for human body or therapeutic component provides new approach.
Specific embodiment
The present invention is not limited by following embodiments, can technology according to the present invention scheme determine specifically with practical situation
Embodiment.It is previously mentioned various chemical reagent and chemical article in the present invention if no special instructions, be known in existing technology
Public chemical reagent and chemical article；Percent in the present invention does not such as have specified otherwise, is mass percent；The present invention
In water such as there is no specified otherwise, be tap water or pure water；If the solution in the present invention does not have specified otherwise, being solvent is
The aqueous solution of water, for example, hydrochloric acid solution is aqueous hydrochloric acid solution；Room temperature in the present invention refers generally to 15 DEG C to 25 DEG C of temperature,
It is commonly defined as 25 DEG C.
With reference to embodiment, the invention will be further described:
Embodiment 1, this pair of sub- acid, obtain as follows: by edible vegetable oil by existing routine techniquess condition successively
Be hydrolyzed saponification, neutralization purification, freeze and separate, finally obtains linoleic acid and the alpha-linolenic acid of sterling, that is, obtains sterling
Double sub- acid, the present invention thes improvement is that in hydrolysis saponification, first adds edible vegetable oil in edible vegetable oil
0.5% to 1% emulsifying agent, then carries out the hydrolysis saponification of routine.Before hydrolysis saponification, in edible vegetable oil
Add emulsifying agent, first make edible vegetable oil and emulsifying agent become dispersion homogeneous, when sodium hydrate aqueous solution adds oil and emulsifying agent
In, you can forming the little microballon of water-in-oil type, thus effectively increasing the surface area that edible vegetable oil hydrolyzes saponification, accelerating anti-
Answer speed, make the hydrolysis saponification of vegetable oil more abundant, can complete to hydrolyze saponification, phase within 1 hour
Ratio in prior art, is obtained double sub- acid using the technology of the present invention, and time of hydrolysis saponification was by 6 hours of prior art to 8
Within hour foreshortens to 1 hour of the present invention, effectively save the production time, improve production efficiency.
Embodiment 2, as the optimization of embodiment 1, emulsifying agent is monoglyceride, sodium stearate, Palmic acid citrate, sucrose
Cetylate, fatty alcohol citrate, fatty glyceride, glycerol monolaurate, polyglycereol castor fatty acid ester, polyglycerol
Cetylate, high-purity powder soybean phospholipid, dextrin, span Tweenses, sucrose polyfatty acid esterses, glycerol fatty acid ester, polyglycereol fat
Acid esters, sorbitan fatty acid ester or citrate.Monoglyceride is a kind of nonionic surfactant, mainly by length containing c18
Chain fatty acid and glycerol carry out esterification and obtain, and have the constituent similar to edible vegetable oil, the existing parent of monoglyceride
Water has lipophilic group again, has the several functions such as moistening, emulsifying, foaming, and main application makes emulsifying agent and the additive of food,
In the present invention as emulsifying agent.The principle that emulsifying agent selects must not be and introduced any element impairing one's health and impurity, does not draw
Enter harmful substance, and can be removed by subsequent technique, be only similar to monoglyceride and sodium stearate such emulsifying agent ability
Use, because monoglyceride is the glyceride of c18 long-chain fatty acid, experienced the course of reaction same with vegetable oil, glycerol is with water
Wash and eliminate, 18 carbonic acid (stearic acid) remove with separating after freezing, and the stearic acid after sodium stearate hydrolysis is with freeze and separate
Remove, do not affect double sub- acid quality.
Embodiment 3, the preparation method of this pair of sub- acid, carry out as follows: by edible vegetable oil by existing routine skill
Art condition be hydrolyzed successively saponification, neutralization purification, freeze and separate, finally obtain linoleic acid and the alpha-linolenic acid of sterling,
Obtain the double sub- acid of sterling, the present invention thes improvement is that in hydrolysis saponification, first adds in edible vegetable oil
The emulsifying agent of edible vegetable oil 0.5% to 1%, then carries out the hydrolysis saponification of routine.
Embodiment 4, as the optimization of embodiment 3, emulsifying agent is monoglyceride, sodium stearate, Palmic acid citrate, sucrose
Cetylate, fatty alcohol citrate, fatty glyceride, glycerol monolaurate, polyglycereol castor fatty acid ester, polyglycerol
Cetylate, high-purity powder soybean phospholipid, dextrin, span Tweenses, sucrose polyfatty acid esterses, glycerol fatty acid ester, polyglycereol fat
Acid esters, sorbitan fatty acid ester or citrate.
Embodiment 5, double Asias acid supplement that double Asia acid as described in embodiment 1 or embodiment 2 for this use obtain, by following sides
Method obtains: adds linoleic acid or the alpha-linolenic acid of sterling in double sub- acid, adjusting alpha-linolenic acid with linoleic mass ratio is 1:
0.5 to 3, obtain double Asias acid supplement.Linoleic acid or alpha-linolenic acid using sterling adjust alpha-linolenic acid and linoleic mass ratio
For 1:0.5 to 3 it is easier to operate, and operating result is more accurate, and meanwhile, mass ratio is alpha-linolenic acid and the Asia oil of 1:0.5 to 3
Double Asias acid supplement of sour compatibility is more conducive to absorption of human body, and effect is more preferable；Double Asias acid supplement can be administered orally or can make capsule
Or hard fat and other dosage form, the such as suitable dosage form of mouthfeel such as drop, Emulsion, powder breast, electuary, honeyed pill.
Embodiment 6, as the optimization of embodiment 5, double Asias acid supplement exists in oily form.Due to sterling linoleic acid or
Alpha-linolenic acid exposes and is easily oxidized in atmosphere, and therefore, double Asias acid supplement exists in oily form and can protect well
Linoleic acid or alpha-linolenic acid, effectively extend the holding time.
Embodiment 7, as the optimization of embodiment 5 and embodiment 6, adds 1% to 10% Flos Carthami in the acid supplement of double Asias
Extract；Or/and, add 1% to 10% lycopene in the acid supplement of double Asias；Or/and, add in the acid supplement of double Asias
1% to 30% phylloxanthin；Or/and, add 1% to 40% anthocyanidin in the acid supplement of double Asias；Or/and, to double Asias processed with acid
1% to 20% Radix Ginseng powder is added in agent；Or/and, add 1% to 20% Stichopus japonicus powder in the acid supplement of double Asias；Or/and, to
1% to 20% Radix Codonopsis powder is added in the acid supplement of double Asias；Or/and, add 1% to 20% Armillaria mellea in the acid supplement of double Asias；
Or/and, add 1% to 40% lecithin in the acid supplement of double Asias；Or/and, add 1% to 20% in the acid supplement of double Asias
Propolis.Double Asia acid are to improve lipid metabolism, keep blood vessel elasticity, adjustment blood fat, the nutrition nucleic of nootropics growth, with double Asias
The material of acid supplement mixing also must be the nutrient needed for strengthening and supplementary body, can be used as medicine, health product, work(
Energy food, bread and cheese and nutrient product, are mainly used in preventing and treating and the preventive treatment of disease of metabolic disease.Double sub- acid are to existing physiology
The effective ingredients in plant of function has positive cooperativity, the such as collaborative more preferable blood circulation promoting and blood stasis dispelling of Flos Carthami extract；Collaborative lycopene is more
Good antioxidation；Collaborative phylloxanthin preferably improves vision etc., must not add and have the collaborative chemical composition subtracted each other, add lecithin
Fat is it is also possible to add the nutrient of the human body easily shortages such as taurine, arginine, the liver protecting function, for spies such as diabetes
Different crowd, provides nutrition for special population, and double Asias acid supplement of the present embodiment belongs to medicine, health product, field of food, Ke Yiding
Measure for nursing one's health blood fat, keep blood vessel elasticity, feed nutrition, prevent metabolic disease.
Embodiment 8, as the optimization of embodiment 5, embodiment 6 and embodiment 7, adds 1% to 5% in the acid supplement of double Asias
Protein；Or/and, add 0.1% to 10% vitamin b in the acid supplement of double Asias；Or/and, add in the acid supplement of double Asias
Enter 1% to 10% vitamin c；Or/and, add 0.1% to 5% vitamin a in the acid supplement of double Asias；Or/and, Xiang Shuanya
0.1% to 5% vitamin d is added in acid supplement；Or/and, add trace element in the acid supplement of double Asias.In the acid supplement of double Asias
The vitamin in national standard and the element such as trace element-selenium, ferrum, calcium, zinc, magnesium can be added, can by means of this pair of sub- acid supplement
To supplement vitamin and the trace element of human body shortage, double Asias acid supplement of the present embodiment belongs to medicine, health product, food neck
Domain, can quantitatively be used for nursing one's health blood fat, keep blood vessel elasticity, feed nutrition, prevent metabolic disease.
The method that the present invention produces double sub- acid is quick, effectively shortens production time, improve production efficiency, and the present invention's is double sub-
Acid supplement can effectively solve the problem that double sub- acid inharmonic problems of picked-up ratio in resident's ordinary meal edible oil, can be used as edible
The a kind of of oil corrects agent and supplement.
Double Asias acid supplement, in addition to the supplement as edible oil, directly can also provide prevention for metabolic disease and control
Treat, double Asia acid are essential fatty acid, be two nutrition nucleic that growth in humans develops, as long as double Asia acid simultaneously enters machine in proportion
Body, just can play and improve lipid metabolism, safeguard blood vessel elasticity, the effect of defying age and disease preventing and treating and preventive treatment of disease, such as adjust
Blood lipid level, steady blood pressure, antithrombotic, prophylaxis of cancer, the intelligence that improves, protection vision, anti-ageing waits for a long time.
Double Asias acid supplement solves metabolic disease and proves effective very much, and taking hyperlipidemia as a example, hyperlipemia is one of blood plasma
Or several lipid is higher than normal, can behave as hypercholesterolemia, hypertriglyceridemia, or both have (the high fat of mixed type concurrently
Mass formed by blood stasis).Continuous improvement with living standards of the people and the change of dietary structure, the sickness rate of hyperlipemia is in rise year by year
Trend.Hyperlipemia is the primary risk factor of atherosclerosiss (as), and the cardiovascular and cerebrovascular disease caused by as is currently to jeopardize
One of principal disease of human health and life.Therefore, effectively control blood lipid level, it has also become medical circle prevents and treats cardiovascular and cerebrovascular vessel
The common recognition of disease.Apply because Western medicine is long-time there is certain side effect, and double Asias acid supplement of the present invention can reach anti-
Control the purpose of hyperlipemia, safety is good, has broad application prospects.
The medical expense being spent by cardiovascular disease and lost work exceed 200,000,000,000 yuan every year for China, to society and
Family causes white elephant.Result of study both domestic and external shows, in cardiovascular and cerebrovascular disease pathogenic factorss, inherited genetic factorss only account for 15%,
Individual lifestyle but accounts for 60%, it can thus be appreciated that the morbidity of cardiovascular and cerebrovascular disease can pass through healthy lifestyles and active drug
To prevent and treat, that is, the mankind can be by correct life style or the medicine seeking Nantural non-toxic evil or health product or food
To adjust body, to reach purpose that is long-lived and improving quality of life.
Double Asias acid supplement is different with edible oil, and different on consumption first, edible oil enters body, be through biology
Chemical process discharges what fatty acid was just absorbed by organisms, if directly eating double Asias acid supplement, can be fixed according to individual variation
Amount is taken in, and to reduce the process of vivo biodistribution chemistry, improves the bioavailability of bisgallic acid.It is demonstrated experimentally that with 4 grams of double Asias acid supplements
60 grams of edible oil effects containing double sub- acid just can be reached, that is, double Asias acid supplements are supplement body linoleic acid and alpha-linolenic acid effective
Approach.
1st, double Asias acid supplements can effectively prevent and treat following disease:
(1) cardiovascular and cerebrovascular disease: include hyperlipemia, hypertension, atherosclerosiss, thrombosiss (hemagglutinin disease
Disease), myocardial infarction, arrhythmia and sudden cardiac death, Thrombotic stroke.
(2) inflammation and autoimmune disease: include rheumatic arthritis, chronic enteritiss, asthma, psoriasises, erythema wolf
Skin ulcer, multiple sclerosis etc..
(3) spirit/neuropathy: include depression, psychotic disorder, senile cerebral degenerative sexually transmitted disease (STD) (alzheimer disease
Disease), epilepsy, childhood hyperkinetic syndrome and distractibility etc..
(4) tumor: include breast carcinoma, colon cancer, carcinoma of prostate, tumor cachexia.
(5) diabetes: the morbidity of inclusion type 1 diabetes and type 2 diabetes mellitus, insulin resistance, following cardiac disease.
(6) kidney illness: include immunity glomerulonephritiies, iga (immunity) type nephropathy, renal failure, nephropathy comprehensively
Levy, renal calculuss.
(7) Pulmonary Diseases: include chronic obstructive pulmonary disease, cystic fibrosises, asthma.
(8) obstetrical and gynecological disease: include fat warp, postmenopausal osteoporosiss, trimester of pregnancy and postpartum depression, preeclampsia, pregnant
Be pregnent phase diabetes, premature labor, low birthweight infant etc..
(9) brain development: include fetus, infant brain normal development, premature infant cerebral hypoplasia (as vision,
Learning capacity is low).
(10) ophthalmology illness: include retinal degeneration sexually transmitted disease (STD), glaucoma, cataract.
(11) other: include toxemia, migraine, senile osteoporosises, skin sufferer (as dermatitis etc.).
2nd, biochemical theory
Oils and fatss (triglyceride) enter to need in vivo to carry out biochemical reaction to discharge fatty acid and just can be absorbed by organisms
, first mix with bile, pancreatic secretion in duodenum, emulsifying forms tiny capsules, is hydrolyzed into fatty acid and is inhaled in small intestinal
Receive.Digested in vivo due to oils and fatss, absorb and have a physical and chemical process, therefore bioavailability is relatively low, such as alone Semen Flos Carthami
Oily cholesterol reducing, zoopery confirms that everyone need to can be only achieved ideal effect with 60g/d, and double Asias acid supplement only needs to 4g, bright
Show and improve bioavailability.
3rd, the clinical test results of double Asias acid supplement
Select the positive control medicine (national quasi-font size medicine) that Radix Oenotherae erythrosepalae oil is clinical trial, this medicine is used for preventing and treating tremulous pulse
The diseases such as hardening, reduction blood fat, its outward appearance is basically identical with double Asias acid supplement, and toxic and side effects are few, have one to disorders of lipid metabolism disease
Determine therapeutical effect, and normal lipid is had no significant effect, comparatively safe for clinical trial.Clinical trial is selected in 99 altogether；Its
Middle test group is selected in 66；Matched group 33.Before treatment, test group, matched group be at sex, nationality, age, and course of disease situation
And degree, merge comparing difference not statistically significant (p ＞ 0.05) between other diseases, drug combination etc. aspect group, Huan Zheji
Line equilibrium is comparable.Result shows, double Asia acid supplements drug effect compared with being used alone safflower oil or being used alone nitration mixture greatly
Improve, reach the requirement of clinical treatment hyperlipidemia.
Therapeutic evaluation: the leading indicator triglyceride tg of clinical trial, test group clinical effective rate is 73.77% (n=
61), matched group is 60.0% (n=30), close with the laboratory result of drug effect, and the clinical effective rate of double Asias acid supplement is than country
Quasi- word medicine Radix Oenotherae erythrosepalae oil exceeds 13.77 percentage points, illustrates that double Asias acid supplement is applied to the high crowd of triglyceride and takes.
Safety evaluatio: clinical trial be used for safety evaluatio every lab index do not find relevant with trial drug
Abnormal change and adverse events occur.Because it is nutrition nucleic needed by human that double Asias acid supplement is made up of essential fatty acid,
Therefore manifested the safety index not having toxic and side effects.
From the high unity effect of animal pharmacodynamic experiment, clinical trial and more than ten years among the people application, fully manifest double
Sub- acid supplement, in effect of preventing and treating cardiovascular and cerebrovascular disease and adjustment lipid aspects, is that other adjustment blood fat group foods can not be compared
, to be the mankind reach preventing and treating cardiovascular and cerebrovascular disease by edible oil approach and two kinds of essential fatty acid ratios of adjustment opens newly
Approach.
From the viewpoint of " integration of edible and medicinal herbs ", double Asias acid supplement has the effect that preventing and treating takes into account, existing therapeutical effect, has pre- again
Anti- effect, because consumption is few, is that same dose of edible oil can not can achieve the effect that.Medicine is accumulation and the distillation of food, but returns
Root knot bottom is to eat as this, and double Asia acid are all the effective ingredient obtaining from natural plants, is that human survival is required with grow
Nutrition does not have potential safety hazard.
At present, reduce cholesterol and the clinical application synthetic drug of triglyceride is more, such as " Statins " pravastatin,
Reach lipid-lowering effect by suppressing body cholesterol biosynthesis rate-limiting enzyme, because body itself enzyme is limited, reduce this enzyme
Other physiological functions, just create either large or small toxic and side effects.And double sub- sour different, its composition comes from vegetable oil, belongs to
Natural " green " composition.
Double Asias acid supplements cannot be used for heating cooking food, but can be administered orally and modulate cold dish although somewhat pungent flavour,
But convenient and instant.
As described in embodiment 7 and embodiment 8, in view of the peculiar effect of double Asias acid supplement itself and safety, by double sub- acid
Preparation adds the edible animals and plants composition that body is beneficial to as effective carrier in other words as a kind of substrate, allows two lifes
Life nucleic can play to the new synergism adding composition on the basis of maintaining self-acting, strengthens these edible animals and plants
The physiological function of composition, accepts and takes in special dietary for human body or therapeutic component provides new approach.
Verify the synergism of the double Asias acid supplement as described in embodiment 7 or embodiment 8 below, with the acid supplement of double Asias
As a example adding the pharmacodynamic experiment of carthamin, investigate double Asias acid supplement to the new collaborative summation action adding composition.
3.1st, lipid-lowering test
Take healthy kunming mice 80, every group 10, male and female half and half, by sex body weight random packet, if blank, height
Fat model, positive control (Xuezhikang), double Asia acid+carthamin low dose of (abbreviation compatibility), agent, the high agent of compatibility, Semen Flos Carthami in compatibility
Oil, 8 groups of carthamin, point cage adaptability raises 1d.
In addition to the blank control group daily morning gives the comparison of 0.5ml distilled water, remaining each group every gavage of the daily morning
0.5ml modeling Emulsion；Daily afternoon, each administration group pressed metering administration (dosage is shown in Table 1), blank control group and high fat respectively
Model control group gives equal-volume distilled water.Successive administration 14d, weighs after last dose, and water 12h is can't help in fasting, and carotid artery takes
Blood, standing 30min 3000rpm centrifugation 15min prepares serum, and full automatic biochemical apparatus measure serum total cholesterol (cho), glycerol
Three esters (tg), high density lipoprotein (hdl-c), low density lipoprotein, LDL (ldl-c) content, experimental result is shown in Table 2.
Each administration group contrast hyperlipidemia model group cholesterol (cho) value all has reduction, and wherein (gallbladder is solid for the middle and high dosage group of compatibility
Alcohol) cho reduce there is statistical significance (p < 0.05)；Visible to the statistics of triglyceride (tg), each administration group tg and model group
More all decrease, wherein middle and high dose of group of compatibility reduction has statistical significance (p < 0.05)；Contrast each group serum is (highly dense
Degree lipoprotein) hdl content, each administration group contrast hyperlipidemia model group slightly raises, and compatibility middle and high dose of group rising has statistics meaning
Adopted (p < 0.05)；Positive control, double Asia acid supplements and each compatibility dosage group ldl value contrast hyperlipidemia model group all have reduction, compatibility
High dose group result has statistical significance (p < 0.05).
3.2nd, anticoagulation experiment
Take healthy Kunming mouse 80, be divided into 8 groups at random according to body weight, every group 10, male and female half and half, by 0.2ml/
10g dosage gastric infusion, awards normal saline, double Asias acid supplement, carthamin (without polysaccharide), carthamin respectively (containing many
Sugar), the carthamin+bis- sub- acid basic, normal, high dosage groups of compatibility and aspirin positive drug control group.
In addition to Normal group, remaining each group is all with gastric infusion after carboxymethyl carboxylic acid sodium solution and medicine mixing.Medicine
Compound method is shown in Table 3.After last dose 30min, gather mouse blood sodium citrate anticoagulant anticoagulant, 1000r/min is centrifuged
10min prepares blood plasma, and coagulo meter measures prothrombin time (pt), and experimental result is shown in Table 4.
Test result indicate that, the prothrombin time of each administration group has substantially compared with blank control group (normal saline gavage)
Extend.Compatibility middle and high dosage group prothrombin time is respectively 9.95s, 10.07s, has significant difference compared with blank control group,
Suitable with positive control drug.
Total result: double Asias acid supplements, carthamin, each dosage group of compatibility are to being caused due to high lipoprotein emulsion gavage modeling
In hyperlipidemia model mice serum, the rising of cho, tg, ldl all has certain inhibitory action, and the reduction to hdl has rising to act on, from
Effect experiment result is observed, and double Asias acid supplement, carthamin, each dosage group of both compatibilities all can show the effect of reduction blood fat,
Mix preparation after both compatibilities shows certain dose-dependant.Double Asias acid supplement, carthamin, each dosage group of compatibility can be prolonged
The prothrombin time (pt) of long mice, has certain blood coagulation resisting function, and the mix preparation after compatibility presents certain journey
The dose-effect relationship of degree.By the pharmacodynamic experiment research of carthamin and double Asias acid supplement compatibility, have after showing both compatibilities
Preferably effect for reducing blood fat and blood coagulation resisting function, the novel form for both compatibilities of research and development further provides scientific basis.
The method that the present invention produces double sub- acid is quick, effectively shortens production time, improve production efficiency, and the present invention's is double sub-
Acid supplement can effectively solve the problem that double sub- acid inharmonic problems of picked-up ratio in resident's ordinary meal edible oil, can be used as edible
The a kind of of oil corrects agent and supplement, directly can also provide prevention and treatment for metabolic disease, can play and improve lipid generation
Thank, safeguard blood vessel elasticity, defying age and disease preventing and treating and the effect of preventive treatment of disease, the purpose preventing and treating hyperlipemia can be reached,
Safety is good, has broad application prospects, and belongs to natural " green " composition, is simultaneously introduced the edible animals and plants that body is beneficial to
Composition, two life nucleic can be played on the basis of maintaining self-acting to the new synergism adding composition, strengthening
The physiological function of these edible animals and plants compositions, accepts and takes in special dietary for human body or therapeutic component provides new approach.
Above technical characteristic constitutes embodiments of the invention, and it has stronger adaptability and implementation result, can basis
It is actually needed the non-essential technical characteristic of increase and decrease, to meet the demand of different situations.
Table 1 each group dosage (lipid-loweringing drug effect)
Impact (n=10) to laboratory animal blood fat after the administration of table 2 each dosage group
#P < 0.05,##P < 0.01, is compared with blank group；*P < 0.05,**P < 0.01, is compared with model group.
Table 3 each group dosage (anticoagulant drug effect)
The impact to mice prothrombin time for table 4 carthamin
Note: * and blank group are than p < 0.05；* and blank group are than p < 0.01.
Claims (8)
1. a kind of double sub- acid, obtains: edible vegetable oil is hydrolyzed successively by existing routine techniquess condition as follows
Saponification, neutralization purification, freeze and separate, finally obtain linoleic acid and the alpha-linolenic acid of sterling, that is, obtain the double sub- acid of sterling,
It is characterized in that in hydrolysis saponification, first adding the emulsifying agent of edible vegetable oil 0.5% to 1% in edible vegetable oil, then
Carry out the hydrolysis saponification of routine.
2. double sub- acid according to claim 1 is it is characterised in that emulsifying agent is monoglyceride, sodium stearate, Petiolus Trachycarpi sour lime
Acid esters, sucrose palmitate, fatty alcohol citrate, fatty glyceride, glycerol monolaurate, polyglycereol castor fatty acid
Ester, polyglycerol cetylate, high-purity powder soybean phospholipid, dextrin, span Tweenses, sucrose polyfatty acid esterses, glycerol fatty acid ester,
Polyglyceryl fatty acid ester, sorbitan fatty acid ester or citrate.
3. a kind of preparation method of double sub- acid, is carried out as follows: by edible vegetable oil by existing routine techniquess condition according to
The secondary saponification that is hydrolyzed, neutralization purification, freeze and separate, finally obtain linoleic acid and the alpha-linolenic acid of sterling, that is, obtain pure
The double sub- acid of product is it is characterised in that in hydrolysis saponification, first add edible vegetable oil 0.5% to 1% in edible vegetable oil
Emulsifying agent, then carry out routine hydrolysis saponification.
4. double sub- acid according to claim 3 preparation method it is characterised in that emulsifying agent be monoglyceride, sodium stearate,
Palmic acid citrate, sucrose palmitate, fatty alcohol citrate, fatty glyceride, glycerol monolaurate, polyglycereol castor
Numb fatty acid ester, polyglycerol cetylate, high-purity powder soybean phospholipid, dextrin, span Tweenses, sucrose polyfatty acid esterses, glycerol
Fatty acid ester, polyglyceryl fatty acid ester, sorbitan fatty acid ester or citrate.
5. a kind of double Asia acid supplements being obtained using double Asia acid according to claim 1 and 2 are it is characterised in that by following sides
Method obtains: adds linoleic acid or the alpha-linolenic acid of sterling in double sub- acid, adjusting alpha-linolenic acid with linoleic mass ratio is 1:
0.5 to 3, obtain double Asias acid supplement.
6. double Asia acid supplement according to claim 5 is it is characterised in that double Asias acid supplement exists in oily form.
7. the double Asia acid supplements according to claim 5 or 6 are it is characterised in that add 1% to 10% in the acid supplement of double Asias
Flos Carthami extract；Or/and, add 1% to 10% lycopene in the acid supplement of double Asias；Or/and, add in the acid supplement of double Asias
1% to 30% phylloxanthin；Or/and, add 1% to 40% anthocyanidin in the acid supplement of double Asias；Or/and, in the acid supplement of double Asias
Add 1% to 20% Radix Ginseng powder；Or/and, add 1% to 20% Stichopus japonicus powder in the acid supplement of double Asias；Or/and, to double Asias processed with acid
1% to 20% Radix Codonopsis powder is added in agent；Or/and, add 1% to 20% Armillaria mellea in the acid supplement of double Asias；Or/and, Xiang Shuanya
1% to 40% lecithin is added in acid supplement；Or/and, add 1% to 20% propolis in the acid supplement of double Asias.
8. the double Asia acid supplements according to claim 5 or 6 are it is characterised in that add 1% to 5% egg in the acid supplement of double Asias
White matter；Or/and, add 0.1% to 10% vitamin b in the acid supplement of double Asias；Or/and, to double Asia acid supplements in add 1% to
10% vitamin c；Or/and, add 0.1% to 5% vitamin a in the acid supplement of double Asias；Or/and, add in the acid supplement of double Asias
Enter 0.1% to 5% vitamin d；Or/and, add trace element in the acid supplement of double Asias.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610794308.7A CN106360732A (en) | 2016-08-31 | 2016-08-31 | Linoleic and linolenic acid, preparation method thereof and linoleic and linolenic acid preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610794308.7A CN106360732A (en) | 2016-08-31 | 2016-08-31 | Linoleic and linolenic acid, preparation method thereof and linoleic and linolenic acid preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106360732A true CN106360732A (en) | 2017-02-01 |
Family
ID=57898844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610794308.7A Pending CN106360732A (en) | 2016-08-31 | 2016-08-31 | Linoleic and linolenic acid, preparation method thereof and linoleic and linolenic acid preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106360732A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593470A (en) * | 2003-09-09 | 2005-03-16 | 车鑫 | Compound linolenic acid preparation |
| CN1596884A (en) * | 2004-07-22 | 2005-03-23 | 国家海洋局第一海洋研究所 | Composition containing high content conjugated linoleic acid and its preparation method |
| CN101057661A (en) * | 2007-05-23 | 2007-10-24 | 迪庆香格里拉舒达有机食品有限公司 | Extraction method for alpha-linolenic acid and preparation |
| CN101294170A (en) * | 2008-06-20 | 2008-10-29 | 秦皇岛领先科技发展有限公司 | Method for preparing fatty acid by using lipase hydrolyzation of oil and fat |
| CN101554190A (en) * | 2008-04-09 | 2009-10-14 | 新疆医科大学 | Edible oil containing two types of essential fatty acid |
| CN102628003A (en) * | 2012-04-16 | 2012-08-08 | 广东工业大学 | Method for extracting purified alpha-linolenic acid from linseed oil |
| CN102676594A (en) * | 2012-05-25 | 2012-09-19 | 厦门大学 | Preparation method of gamma-linolenic acid |
| CN104418726A (en) * | 2013-08-20 | 2015-03-18 | 陕西中鼎华盛农业发展有限公司 | Extraction method of [alpha]-linolenic acid |
-
2016
- 2016-08-31 CN CN201610794308.7A patent/CN106360732A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593470A (en) * | 2003-09-09 | 2005-03-16 | 车鑫 | Compound linolenic acid preparation |
| CN1596884A (en) * | 2004-07-22 | 2005-03-23 | 国家海洋局第一海洋研究所 | Composition containing high content conjugated linoleic acid and its preparation method |
| CN101057661A (en) * | 2007-05-23 | 2007-10-24 | 迪庆香格里拉舒达有机食品有限公司 | Extraction method for alpha-linolenic acid and preparation |
| CN101554190A (en) * | 2008-04-09 | 2009-10-14 | 新疆医科大学 | Edible oil containing two types of essential fatty acid |
| CN101294170A (en) * | 2008-06-20 | 2008-10-29 | 秦皇岛领先科技发展有限公司 | Method for preparing fatty acid by using lipase hydrolyzation of oil and fat |
| CN102628003A (en) * | 2012-04-16 | 2012-08-08 | 广东工业大学 | Method for extracting purified alpha-linolenic acid from linseed oil |
| CN102676594A (en) * | 2012-05-25 | 2012-09-19 | 厦门大学 | Preparation method of gamma-linolenic acid |
| CN104418726A (en) * | 2013-08-20 | 2015-03-18 | 陕西中鼎华盛农业发展有限公司 | Extraction method of [alpha]-linolenic acid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69935995T3 (en) | POLYUNGATURATED FATTY ACIDS NUTRITIONAL SUPPLEMENT | |
| RU2552039C2 (en) | Methods and lipid compositions aiding in intestinal flora development | |
| CN101720822A (en) | Nutritional blend oil with balanced fatty acid component and active component for middle and old aged | |
| CN105053256A (en) | Flavored nutrition balanced blend oil | |
| CN103444911A (en) | Medicinal and edible health care blending oil | |
| CN102283386A (en) | Composite camellia oil health care product with function of reducing blood fat and preparation method thereof | |
| TW200744573A (en) | Use of dha and ara in the preparation of a composition for preventing or treating obesity | |
| CN107683909A (en) | The special ready-mixed oil of high fat diet | |
| CN103190619A (en) | Fish oil and linseed oil soft capsules and preparation method thereof | |
| CN106359657A (en) | Nutrition-balanced edible blend oil | |
| CN108703364A (en) | Treating fatty acid metabolism tailored version clinical nutrition formula and preparation method thereof | |
| WO2017032270A1 (en) | Composition for preventing and/or treating cardiovascular and cerebrovascular diseases | |
| CN108703365A (en) | Protein allergy tailored version clinical nutrition formula and preparation method thereof | |
| CN102578307A (en) | Dual-sub-acid high-end vegetable oil and preparation method thereof | |
| CN102018823A (en) | Composite preparation containing phospholipid, alpha-linolenic acid, gamma-linolenic acid and tomato extract | |
| TWI445528B (en) | The use of arachidonic acid as a constituent fatty acid triglyceride for the manufacture of a pharmaceutical composition and a food product for preventing or ameliorating a symptom or a disease caused by aging of the blood vessel caused by a decrease in blood vessel elasticity, The manufacturing method | |
| CN101099562A (en) | Omega-3 unsaturated fatty acids appetizer oil and producing method and application thereof | |
| KR100724165B1 (en) | Natural vegetable oil concentrated in unsaponifiable matters as food ingredient | |
| US20120184760A1 (en) | Removal of monoglycerides from fatty acid concentrates | |
| KR20190040141A (en) | Oil blends and process for their preparation | |
| Lee | Essent ial Fat ty Acids | |
| CN106360732A (en) | Linoleic and linolenic acid, preparation method thereof and linoleic and linolenic acid preparation | |
| CN1298647A (en) | Health-care oil for regulating blood fat | |
| CN106234652A (en) | A kind of vegetable oil composition balanced in nutrition | |
| CN103690821A (en) | Composition for assisting in reducing blood fat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170201 |
|
| RJ01 | Rejection of invention patent application after publication |